The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in ...

Ranibizumab PDS is also under review by the EMA in Europe. The implant is refillable and about the size of a grain of rice, continuously delivering ranibizumab over a period of months.

The international randomized clinical trial, called RAINBOW, compared ranibizumab to laser therapy for the treatment of very low birthweight infants with ROP. The study was funded by Novartis Pharma ...

Ranibizumab is a selective vascular endothelial growth factor (VEGF) antagonist, prescribed for neovascular (wet) age-related macular degeneration (AMD- loss of vision) and macular edema following ...

Patients with diabetic macular edema treated with intravitreal aflibercept have a significantly higher risk of adverse renal events compared with those treated with ranibizumab.

Basel, Switzerland-headquartered Sandoz has signed an agreement to acquire US rights to Cimerli, a biosimilar of Roche and Novartis’ ophthalmology therapy Lucentis (ranibizumab), from Coherus ...

The global ShORe Phase 3 trial evaluated the efficacy and safety of intravitreally administered 2 mg sozinibercept every four or eight weeks in combination with 0.5 mg ranibizumab every four weeks ...

Background To investigate the short-term outcomes of treatment with intravitreal aflibercept in cases with wet age-related macular degeneration (AMD) resistant to ranibizumab. Methods The study ...

Options include ranibizumab, pegaptanib, aflibercept, and verteporfin. Corneal abrasions are conditions in which the eye is ...

One trial evaluated sozinibercept in combination with aflibercept 2 mg (Eylea), the other in combination with ranibizumab 0.5 mg (Lucentis). The comparator in both trials was aflibercept or ...

The first licensed biological anti-VEGF, ranibizumab, entered clinical practice in 2007 and hugely improved prognosis. Challenges remained though. The high cost of the drug and the need for repeated ...